focus
Previous article:
Moonlake's readout produced a cash windfall. Risks remain
Next article: Group behind ProMed defends move to subscription
Next article: Group behind ProMed defends move to subscription
explore
leisure time
-
Alnylam reports growth in sales of rare disease treatments
2025-08-31 07:48 -
A controversial new treatment promises to make little people taller
2025-08-31 07:46 -
What we’ve learned from the Aduhelm mess
2025-08-31 07:45 -
Industry veterans launch new biotech VC with $310M
2025-08-31 07:40 -
Flint parents haunted by uncertainty, fears of lead poisoning
2025-08-31 06:46 -
CDC recommends RSV monoclonal antibody for infants
2025-08-31 06:19